MTOR and hepatocellular carcinoma: Another study focused on the PI3K/Akt/mTOR signaling cascade, as the activities of mTOR inhibitors and sorafenib, arise at separate stages along two pathways, their combination could be complementary and provide further successful suppression of HCC.